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ABSTRACT
We previously reported that ABI3 expression is lost in follicular thyroid 
carcinomas and its restoration significantly inhibited cell growth, invasiveness, 
migration, and reduced tumor growth in vivo. The mechanistic basis by which ABI3 
exerts its tumor suppressive effects is not fully understood. In this study, we show 
that ABI3 is a phosphoprotein. Using proteomic array analysis, we showed that ABI3 
modulated distinct cancer-related pathways in thyroid cancer cells. The KEA analysis 
found that PI3K substrates were enriched and forced expression of ABI3 markedly 
decreased the phosphorylation of AKT and the downstream-targeted protein pGSK3β. 
We next used immunoprecipitation combined with mass spectrometry to identify 
ABI3-interacting proteins that may be involved in modulating/integrating signaling 
pathways. We identified 37 ABI3 partners, including several components of the 
canonical WAVE regulatory complex (WRC) such as WAVE2/CYF1P1/NAP1, suggesting 
that ABI3 function might be regulated through WRC. Both, pharmacological inhibition 
of the PI3K/AKT pathway and mutation at residue S342 of ABI3, which is predicted to 
be phosphorylated by AKT, provided evidences that the non-phosphorylated form of 
ABI3 is preferentially present in the WRC protein complex. Collectively, our findings 
suggest that ABI3 might be a downstream mediator of the PI3K/AKT pathway that 
might disrupt WRC via ABI3 phosphorylation.
INTRODUCTION
We previously reported that ABI3 (ABL-Interactor 
member 3) expression is lost in most thyroid carcinomas, 
compared to benign lesions and normal thyroid tissues. 
Moreover, ABI3 re-expression in a human follicular 
thyroid carcinoma cell line significantly inhibited cell 
proliferation, invasion, and migration in vitro and reduced 
tumor growth in vivo. The partial re-acquisition of a 
less aggressive phenotype was accompanied by increase 
of cellular senescence [1]. We also demonstrated that 
transcriptional silencing of ABI3 in thyroid cancer occurs 
via methylation of specific GpG sites located within the 
ABI3 promoter [2]. These findings suggested that ABI3 act 
as a tumor suppressor gene.
In addition to its suppressive role in thyroid cancer, it 
has been demonstrated that ABI3 expression is frequently 
lost in invasive cancer cell lines. Overexpression of ABI3 
in metastatic glioma cells decreased cell motility and the 
metastasis potential in vivo [3]. It was also demonstrated 
that ABI3 might regulate the remodeling of the actin 
cytoskeleton [4–6]. Moreover, DNA methylation and 
transcriptional silencing of ABI3 was associated with poor-
prognosis in chronic lymphocytic leukemia samples [7].
While the study of the role of ABI3 in cancer has 
been intensified, the precise mechanism by which ABI3 
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exerts its tumor-suppressive effect and/or cytoskeleton 
remodeling in thyroid cells is still unknown.
ABI3 belongs to ABL-interactor (ABI) family 
proteins, which also includes ABI1 and ABI2. ABI 
proteins are a class of cytoplasmic molecular adaptors, 
originally identified as binding partners for the Abl 
kinases, which contain an amino-terminal homeobox 
homologous region (HHR), a proline-rich (PR) region 
and a carboxy-terminal Src-homology 3 (SH3) domain. 
The interaction between ABL and ABI proteins seems to 
involve multiple domains, through which they regulate the 
ABL kinase activity [8].
Up to now, most of studies have focused on the role 
of ABI1 and ABI2 family proteins. It has been shown that 
ABI1 or ABI2 proteins are one of the components of a 
macromolecular complex referred as WAVE regulatory 
complex (WRC). The WRC consist of five-subunit 
protein that includes ABl (ABI1, ABI2 or ABI3), WAVE 
(WAVE1, WAVE2 or WAVE3), Nap1 (also know as 
NCKAP1), Sra1 (also know as Cyfip1), and HSCP300 [9]. 
This heteropentameric complex can be assembled from 
combinations of different isoforms [9–13].
It has been show that ABI1 forms a large protein 
complex including WAVE2, Nap1, Sra1 and HSCP300 
[14]. ABI1 interacts directly with WAVE2 and Nap1 
and couples Abl to WAVE2 in response to signaling. 
The authors also demonstrated that Abl-mediated 
WAVE2 tyrosine phosphorylation is required for actin 
polymerization and remodeling [15].
On the other hand, ABI2 forms a trimer with 
WAVE1 and HSCP300. The two large subunits Sra1 and 
Nap1 form a platform for the WAVE1/ABI2/HSCP300 
trimer. Thus, the proteins are assembled into a mini WRC 
pentamer [16, 17].
It has been suggested that the WRC is maintained in 
an inactive state and disruption of this interface resulted in 
constitutively active complex.
Although ABI3 was recently identified as a 
component of the WRC, it was suggested that it is 
functionally distinct from ABI1-WAVE complex as it 
neither binds to c-ABL nor promotes ABL-mediated 
phosphorylation of WAVE2 [18].
As each component of the WRC complex appears 
exchangeable, identifying members that directly interact 
with ABI3 and the pathway that may control these 
interactions can provide an important framework for 
understating the role of ABI3 in tumor initiation and 
progression.
Here, using proteome-profiling array, we found 
that the tumor suppressive effects of ABI3 reduces 
phosphorylation of AKT and GSKβ. Furthermore, 
immunoprecipitation combined with mass spectrometry 
studies demonstrates that ABI3 interacts with WAVE2 and 
CYFIP1, members of WRC. Mutation at residue S342 of 
ABI3 analysis suggested and pharmacological inhibition 
of the PI3K/AKT pathway (LY294002) suggested that 
ABI3 might be phosphorylated by PI3K/AKT at S342. 
Moreover, our findings suggested that that the non-
phosphorylated form of ABI3 seems to be preferentially 
present in the protein complex. All together, ours results 
suggests that the molecular axis consisting of ABI3/
WAVE2/CYFIP1 might be negatively regulated by PI3K/
AKT pathway in thyroid cells.
RESULTS
ABI3 is expressed as phosphorylated and non-
phosphorylated forms
For functional analysis, a thyroid follicular 
carcinoma cell line (WRO) was permanently transfected 
with phCMV2 expressing the full-length HA-tagged 
ABI3 (HA-phCMV2-ABI3) or with the control vector 
(HA-phCMV2). Western blot analyses with anti-HA 
antibody confirmed the expression of the HA-tagged 
ABI3 protein in WRO cells (Figure 1A). Interestingly, 
two bands were detected: a band at a molecular weight 
(MW) of ~54kDa, and a lower band at the expected size 
of ~52kDa. The presence of two bands was also observed 
when an antibody against ABI3 was tested in both WRO 
and FTC133 cells transected with the HA-tagged ABI3 
expressing construct. These results not only confirm the 
presence of two forms of ABI3 but also suggest that the 
upper band is most likely a phosphorylated form of ABI3 
(Figure 1B).
The putative phosphorylation event was assessed by 
treatment of the protein extract with phosphatase (CIP), 
which catalyzes the removal of phosphate groups from 
proteins and, consequently, is expected to reverse the 
mobility shift in the gel. Western blot analysis showed that 
the upper band disappeared upon CIP treatment in both 
WRO and FTC133 cells. These results indicate that upper 
and lower bands correspond to the phosphorylated and 
non-phosphorylated forms of ABI3, respectively (Figure 
1B). Although it has been previously predicted that ABI3 
is phosphorylated, our results demonstrate, for the first 
time, that ABI3 is a phosphoprotein.
Antibody array proteomic analysis shows that 
ABI3 regulates distinct cancer-related pathways
It is well known that posttranslational modifications, 
such as phosphorylation, are tightly regulated and play 
significant roles in regulating signaling transduction 
pathways. As phosphorylation can rapidly turn on and 
off signaling events, we used an antibody array for 
the simultaneous measurement of relative levels of 
phosphorylation of 46 intracellular serine/threonine/
tyrosine kinases. We additionally assessed the relative 
expression levels of 35 apoptosis-related proteins. 
We considered differentially expressed those with p-
value (P<0.05). As even very small fold-changes might 
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be considered statistically significant, we also ranked 
significant proteins by fold-change. A cut-off of at least 
20% difference (<0.80 for down-regulation or >1.2 for 
up-regulation) between the 2 biological groups (ABI3 
expressing cells vs controls) was used. (Supplementary 
Table 1). Considering both p-value and fold-change criteria 
simultaneously, nearly 26 proteins were down-regulated in 
WRO cells expressing ABI3. Intriguingly, phosphorylation 
of key components of the PI3K/AKT (AKT and 
GSK3α/β), AMPK (AMPKα1 and AMPKα2), mTOR 
(TOR and p70S6 Kinase), p38 MAPK (p38α, MSK1/2 and 
HSP27) and SAPK/JNK (JNK and c-Jun) pathways were 
down-regulated following ABI3 expression. Additionally, 
ABI3 reduces the phosphorylation of Src family of 
cytoplasmic tyrosine kinases (Src, Lyn, Lck, Fyn, Yes, 
Fgr, Pyk2, Hck and FAK), signal transducer and activator 
of transcription factors (STAT2 and STAT5B) and PLCγ-1 
proteins. The expression of β-Catenin and XIAP proteins 
were significantly increased in WRO cell expressing ABI3 
(Supplementary Table 1).
We next applied Kinase Enrichment Analysis (KEA) 
(adjusted P<0.05), an alternative approach to recognize 
signaling pathways activated following ABI3 expression. 
The list of the genes considered statistically significant 
and reported in Supplementary Table 1 (p-value and fold-
change criteria simultaneously) was used as input for 
computing enrichment with existing lists created from 
prior knowledge organized into gene-set libraries [9].
KEA ranked GSK3β, GSK3α, p70S6 Kinase, SRC, 
AKT1, HSP27, CTNNB1, XIAP, PLCγ1 and TOR proteins 
(P=0.021, Z-score=-1,062), are most significantly 
associated. Additionally used the Protein Analysis 
Figure 1: (A) Western blot analysis of WRO cells permanently transfected with HA-phCMV2-ABI3 (HA-ABI3) or HA-phCMV2 empty 
vector (control cells). Two bands were detected: a band at a molecular weight (MW) of ~54kDa, and a lower band at the expected size 
of ~52kDa. (B) CIP treatment of the WRO and FTC133 cellular lysates. The upper band disappeared upon CIP treatment in both WRO 
and FTC133 cells, suggesting that the lower bands correspond to non-phosphorylated forms of ABI3, respectively (C) Representative 
data from Phospho-kinase (ARY003) and apoptosis (ARY009) array analysis. Membranes were incubated with WRO cells expressing 
ABI3 and control. Proteins were either up-regulated (≥ 1.2, ABI3 expressing cells to control) or down-regulated (≤ 0.8, control to ABI3 
expressing cells). (D) Western blot analysis of proteins found down-regulated in the Phospho-kinase array assay. The WRO and FTC133 
cells expressing ABI3 diminished expression of phospho AKT (pAKT) at both T308/S473 and pGSK3β at S9. Numbers represents the 
mean obtained from independent experiments.
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Through Evolutionary Relationships (Panther). This 
approach demonstrated enrichment for the RAS pathway 
(P=0.0009, Z-score=-1,398) (Gene list: JNK1/2, GSK3β, 
JUN, GSK3α, AKT1 and p38α) (P<0.0001). A network 
map portraying the relationships among these proteins in 
the context of cell signaling pathways is shown (Figure 2).
ABI3 diminished phosphorylation of PI3K 
substrates
As PI3K substrates are enriched based on KEA 
analysis, we next validated the expression of key 
components of PI3K pathway by western blotting analysis. 
The forced expression of ABI3 in two follicular thyroid 
carcinoma cell lines (WRO and FTC 133) markedly 
decreased the phosphorylation of AKT at both T308 and 
S473, as well as the phosphorylation of the downstream-
targeted protein pGSK3β at S9 (P<0.05) (Figure 1D).
WAVE 2 and CYFIP1 are ABI3-interacting 
proteins
We next sought to identify ABI3-interacting 
proteins that may be involved in modulating or even 
integrating signaling pathways found modulated by 
antibody proteome array. Total protein extract from WRO 
cells transfected with constructs expressing HA-tagged 
ABI3 was immunoprecipitated with anti-HA antibody, 
henceforward named HA-IP. To distinguish the irrelevant 
background proteins, HA-GFP (Green Fluorescent Protein) 
was used as negative control. To determine the identity of 
co-immunoprecipitated proteins, three independent HA-
IP and HA-GFP were submitted to mass spectrometry 
(MS) analysis. This analysis revealed 77 proteins in all 
IPs. To help to identify the bona fide interacting proteins 
we initially excluded all proteins that appeared only 
in the HA-GFP control samples (25 proteins). For the 
proteins that were identified in both HA-ABI3 and HA-
GFP immunoprecipitations we used LFQ (label free 
quantitation) intensity ratio as a filtering parameter. This 
led to the exclusion of 11 additional proteins which a HA-
ABI3/HA-GFP LFQ intensity ration lower than four-fold. 
Five other proteins were also excluded on the basis that 
there was no detectable LFQ intensity associated to the 
peptides identified for them. By using these criteria, we 
identified 37 proteins with high probability to be ABI3-
binding partners (Supplementary Table 2), including 
three of the five subunits of the WRC complex (WAVE2, 
Figure 2: A network map portraying the relationships among the proteins identified as modulated by ABI3 (orange) 
in the context of cell signaling pathways. The gray proteins were not evaluated in array.
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NAP1and CYFIP1). The list also included other proteins 
that are likely to be involved in the activation of the 
WAVE complex (FABP5, TUBB3, MYH9 and PDIA3) 
(Table 1). Moreover, we identified abundant proteins such 
as actin (ACTBL2), tubulin (TUBA1A) and tropomyosin 
(TPM1). As WRC controls actin cytosleletal dynamics, 
it may represent specific protein interactions rather than 
contaminant proteins.
Based in the fact that WAVE2 was identified as 
putative interacting partner of ABI3 in non-thyroid cells [4] 
and that WAVE2 and CYFIP1 may participate in the same 
protein complex, the association of ABI3 with WAVE2 
and CYFIP1 was validated by co-immunoprecipitation 
followed by western blot experiments. We found that 
ectopically expressed ABI3 co-immunoprecipitated with 
WAVE2 and CYFIP1 in both cell lines (Figure 3A). To 
further investigate the interplay between ABI3, WAVE2 
and CYFIP1, we ectopically expressed the full length HA-
tagged ABI3 in WRO and FTC133 cells and performed 
IP using the anti-WAVE2 antibody (WAVE2-IP). ABI3 
and CYFIP1 co-immunoprecipitated with WAVE2 in both 
WRO and FTC133 cells, suggesting that these proteins 
physically interact (Figure 3B). Interestingly, when cell 
lysate extracted from WRO and FTC133 cells were probed 
with anti-WAVE2 antibody, the non-phosphorylated form 
of ABI3 (lower migration protein band) preferentially co-
precipitated with WAVE 2 in both cell lines (Figure 3B). 
These findings may suggest that phosphorylation of ABI3 
may generate an inactive form of ABI3 that is unable to 
interact withWAVE2.
Mutation of ABI3 at residue S342A affects the 
expression of phosphorylated form of ABI3
Once CIP treatment indicates that ABI3 is a 
phosphoprotein (Figure 1B), ABI3 ectopic expression 
significantly inhibited AKT/GSK3β phosphorylation 
in thyroid carcinoma cells (Figure 1C and 1D), and 
phosphorylated form of ABI3 might represent an 
inactive form of the protein (Figure 3B), we next 
searched for putative phosphorylation sites using in silico 
analysis and data available from literature. Databases 
(PhosphoSite Plus, UniProt and HPRD) were used to 
search for the exact position of known as well as putative 
phosphorylation sites. We additionally used Scansite3 to 
identify which families of kinase would be most likely to 
phosphorylate a given substrate. Twelve phosphorylation 
sites were identified in the PhosphoSite Plus database 
(Supplementary Table 3). ABI3 has been previously 
reported to be phosphorylated at S213, S216 and Y341by 
mass spectrometry analysis [17, 19–21]. Proteomic and 
phosphoproteomic characterization also showed that ABI3 
was phosphorylated at S342 in mouse and human tissues 
[17, 19–21].
Although these analyses demonstrated that ABI3 is a 
target of multiple phosphorylations, for most of them, the 
biological significance is largely unknown. Interestingly, 
the Scansite3 predicts T165 and S342 are potential 
phosphorylation sites for AKT and S202 is a potential 
phosphorylation site for GSK3β.
As the ABI3 residue S342 is located within SH3 
domain, which is one of the most well-known protein 
domains associated with signaling involved in most basic 
cellular processes as well as in pathological conditions 
such malignant transformation, and the conservation 
of phosphosites has been used to underscore sites that 
are more likely to be functionally relevant, we next 
investigated whether S342 is highly conserved in other 
species such as Macaca mulatta, Canis lupus familiaris, 
Bos Taurus, Mus musculus and Rattus norvegicus. Using 
phosphosite, the S342 is extremely conserved (100%) 
among species examined, which further confirm that this 
site is likely to be involved in related signaling networks 
with functionally important roles (Supplementary Figure 
1).
As an initial attempt to determine whether the S342 
is critical for the ABI3 phosphorylation, we constructed 
an ABI3 mutant clone in which the candidate Serine was 
replaced to Alanine (S342A). WRO cells expressing the 
ABI3-S342A mutant preferentially expressed the non-
phosphorylated form of ABI3 (Figure 3C, P<0.05).
Moreover, cells were treated with LY294002, a 
PI3K/AKT potent pharmacological inhibitor. As expected, 
the LY294002 treatment abolishes AKT phosphorylation 
at S473 in WRO cells and attenuates its phosphorylation in 
FTC133 cells (Figure 3C). Inhibition of AKT activity was 
accompanied by a concomitant increase in the expression 
level of non-phosphorylated form of ABI3 (52 kDa), with 
respect to its phosphorylated form (54 kDa) (P=0.0125; 
Figure 3C).
The magnitude of the band shift toward the non-
phosphorylated form (lower band) in the WRO cells 
expressing ABI3 Wild type (Wt) following LY294002 
treatment is comparable to that seen in ABI3-S342A 
mutant, independently of the treatment with LY294002. 
In FTC133 cells the shift toward the non-phosphorylated 
form was even higher in the ABI3-S342A mutant. These 
results, graphically represented, may suggest that other 
protein/signaling pathway might phosphorylate S342 in 
this cell line (Figure 3C).
ABI3 may interact with WRC in a PI3K/AKT 
dependent way
As the experimental results presented above suggest 
that WAVE2 and CYF1P1 directly interact with ABI3 
and that PI3K/AKT pathway may regulates the basal 
activity of ABI3, we next investigate whether PI3K/AKT 
inhibitors may affect protein interactions. To this, WRO 
and FTC133 cells ectopically expressing ABI3 were 
treated with LY294002. The whole-cell extracts (WCE) 
was immunoprecipitated with anti-WAVE2 antibody and 
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Figure 3: (A) ABI3 co-immunoprecipitated with WAVE2 and CYFIP1 in WRO and FTC133 cells evaluated by HA immunoprecipitation. 
(B) WAVE2 immunoprecipitation (WAVE2-IP) confirms that WAVE2, ABI3 and CYFIP1 participate in the same protein complex. The 
lower band of ABI3 preferentially co-Immunoprecipitates with the protein complex. (C) LY294002 treatment showing that the inhibition 
of AKT pathway concurrently increased the levels of non-phosphorylated ABI3 (lower band). The same increased in the levels of non-
phosphorylated ABI3 was observed in ABI3 S342A mutant independently of LY294002 treatment, suggesting that this site was responsible 
to the modulation observed in ABI3 wt. Values in the graphics represents the mean obtained from independent experiments.
Table 1: List of proteins that are likely to be involved in the activation of the WAVE regulatory complex identified by 
mass spectrometric analysis
Protein
HA-ABI3/HA-EGFPb
HA-IP 1 a HA-IP 2 a HA-IP 3 a
WAVE2 (WASF2) 2/0 3/0 2/0
CYFIP1 4/0 5/0 8/0
NCKAP1 0/0 1/0 1/0
FABP5 0/0 1/0 1/0
TUBB3 0/0 1/0 1/0
MYH9 14/5 33/24 42/5
PDIA3 2/0 2/3 3/0
aHA IP: HA-ABI3 immunoprecipitation.
bUnique Peptides.
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the quantity of ABI3, WAVE2 and CYFIP1 was measured 
by western-blot. Two independent WAVE2-IP were 
carried out for each experiment and one representative 
result is shown in Figure 4. In WRO cells, we observed 
a significant increase in co-immunoprecipitation of the 
three proteins (p<0.05) suggesting that inhibition of the 
PI3K/AKT pathway induced an increased in ABI3 non-
phosphorylated form as well as lead to an increase in its 
affinity to WAVE2 and CYF1P1. Although not statically 
significant, similar results were observed in FTC133 cells.
ABI3 expression positively correlates with 
WAVE2 and CYFIP1 in thyroid tissues
We previously demonstrated ABI3 is expressed in 
normal thyroid and follicular thyroid adenoma (FTA), 
while its expression is lost in most follicular thyroid 
carcinomas. Therefore, to be able to investigate a 
correlation among ABI3/WAVE2/CYF1P1 expression in 
thyroid samples, normal thyroid tissues and FTA were 
chosen to assess the expression of ABI3 WAVE2 and 
CYF1P1 by qRT-PCR. We observed a significant positive 
correlation between the mRNA expression of ABI3, 
WAVE2 and CYFIP1 in both FTA and normal thyroid 
tissues (p<0.05) (Figure 5A). As most thyroid carcinomas 
did not express ABI3, the correlation among ABI3, WAVE2 
and CYFIP1 was not performed in this set of samples.
Since a positive correlation was seen in thyroid 
tissues, the correlation analysis was also performed in 
follicular thyroid carcinoma cell lines that ectopically 
expressed ABI3. An increase in the levels of the CYFIP1 
and WAVE2 proteins in WRO cells expressing ABI3 as 
compared to control that do not express ABI3 (empty 
vector) (p<0.05). Although not statically significant, we 
observed a similar tendency in FTC133 cells (Figure 5B).
DISCUSSION
We previously showed that ectopic expression of 
ABI3 in a follicular thyroid cancer cell line inhibited cell 
growth, invasiveness and migration in vitro, and reduced 
tumor growth in vivo [22]. We also demonstrated that 
transcriptional silencing of ABI3 in follicular thyroid 
cancer cells and follicular thyroid tumors occurs via 
methylation of specific GpG sites located within the ABI3 
promoter [2]. Although our findings provide evidences 
to support classification of ABI3 as a bona fide tumor 
suppressor gene, the precise mechanism by which ABI3 
exerts its function is still unknown.
As far as we know, we report here for the first 
time that ABI3 can occur in phosphorylated and non-
phosphorylated forms. As phosphorylation can either 
activate or inactivate signaling pathways, we profiled 
the phospho-kinase screening array to interrogate the 
Figure 4: Co-immunoprecipitation of ABI3, WAVE2 and CYFIP1 after LY294002 treatment showing that AKT 
pathway not only interfere in ABI3 phosphorylation but also in its affinity to WRC complex. WCE = Whole Cell Extract. 
Numbers represents the mean obtained from independent experiments.
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signaling pathways that are regulated by ABI3. Our 
phosphoprotein array analysis shows that re-expression of 
ABI3 down-regulates the phosphorylation of components 
of the PI3K/AKT, AMPK, mTOR, p38 MAPK and 
SAPK/JNK pathways. To illustrate the interconnection 
between the pathways, the 5-top pathways we manually 
combined into a single map (Figure 2). Down-regulation 
of these pathways, known as crucial to tumor growth and 
differentiation in different tumors subtypes [23–25], can 
explain, at least in part, the biological effects observed 
following forced expression of ABI3 in follicular thyroid 
carcinoma cells [22].
As the most significant enriched pathway was the 
PI3K/AKT, we next investigated the activity of major 
downstream effectors of PI3K. ABI3 expression inhibited 
AKT phosphorylation (S473 and T308), as well as, 
GSK3β phosphorylation (Ser9).
We also found that ABI3 up-regulates β-Catenin. It 
was previously reported that PI3K/AKT/GSK3β pathway 
regulates β-Catenin activity [26] and that down-regulation 
of β-catenin expression is associated with more aggressive 
tumor phenotypes [27]. However, additional studies are 
needed to better clarify whether ABI3 may link PI3K/
AKT/GSK3β and β-Catenin pathways in thyroid cells.
Figure 5: (A) Expression of ABI3, WAVE2 and CYFIP1 in normal thyroid tissue and FTA by quantitative RT-PCR. A significant positive 
correlation was found between the expression of ABI3, WAVE2 and CYFIP1 in thyroid samples. (B) WRO and FTC133 cells ectopically 
expressing ABI3 also showed high level of WAVE2 and CYFIP1 protein expression. Numbers represents the mean obtained from 
independent experiments.
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Importantly, up-regulation of the PI3K/AKT 
pathway is an important mechanism associated with 
pathogenesis, as well as, with the progression of thyroid 
cancer [25, 28].
To better understand how ABI3 could interact with 
PI3K/AKT pathway, immunoprecipitation combined with 
mass spectroscopy analysis was used to pull-down protein 
complex and identify those that may interact with ABI3. 
We identified 37 proteins that can potentially associate 
with ABI3 and form different types of complexes, 
including components of the canonical WAVE regulatory 
complex (WRC) such as CYF1P1, WAVE2 and NAP1. 
Therefore, the ABI3-WAVE2-CYFIP1 interaction was 
validated by co-immunoprecipitation assays. The three 
proteins were co-immunoprecipitated by anti-ABI3 or 
anti-WAVE2 specific antibodies. Collectively, these data 
corroborate the results obtained with mass spectrometry, 
and indicate that WAVE2 and CYF1P1 are interacting 
partners for the ABI3 protein.
We further show that mutation at S342A and 
LY294002 treatment increases the expression level of non-
phosphorylated form of ABI3, suggesting that PI3K/AKT 
potentially phosphorylates ABI3 at S342. Interestingly, the 
S342 site is located within the SH3 domain of ABI3. It 
has been suggested that the SH3 domain and the proline-
rich region found in ABI3 are involved in the interaction 
with others proteins or complexes [8]. In addition, 
phosphorylation is a mechanism involved in WRC 
activation and may influence in the complex conformation 
[15, 16, 29]. However, the phosphorylation pattern of the 
members of WRC and their activating kinases are largely 
unknown.
We observed here in immunoprecipitation 
assays that the non-phosphorylated form of ABI3 is 
preferentially found in association with the protein 
complex. Furthermore, our data suggest that AKT may 
interfere in WRC formation probably by modulation the 
phosphorylation state of ABI3. We propose that when 
the AKT pathway is activated, ABI3 is phosphorylated 
by AKT at residue S342, which inhibits the formation 
of WRC complex. On the other hand, when the AKT 
pathway is inhibited with LY294002, ABI3 ceases to be 
phosphorylated by AKT and the WRC complex can be to 
be formed (Figure 6).
Remarkably, WRC can be assembled through 
associations of different isoforms of five proteins: ABI 
(ABI1, ABI2 and ABI3), Cyfip1/Sra-1 (Cyfip2/PIR121), 
Nap1 (Hem1), WAVE (WAVE1, WAVE2 and WAVE3) 
and HSPC300/Brck-1. WRC has been involved in many 
cellular processes associate with cytoskeleton dynamics 
including the maintenance of cell shape and morphology, 
cytokinesis, adhesion, migration, endocytosis and 
phagocytosis. Dysregulation of WRC components have 
been associated with cancer development, as well as, 
metastasis [30–37]. Down-regulation of WAVE2 was 
associated with a metastatic phenotype in gastric cancer, 
melanoma cells and adenocarcinoma of the lung [31–33]. 
Reduced expression of CYFIP1 was also observed during 
Figure 6: Model describing the putative crosstalk between the PI3K/AKT and WAVE regulatory complex (WRC) 
in thyroid cells via ABI3. Our data suggests a model whereby PI3K/AKT signaling might control ABI3 phosphorylation at S342. 
Phosphorylation of ABI3 by AKT inhibits the formation of WRC. In presence of LY294002, a PI3K/AKT inhibitor, the non-phosphorylated 
form of ABI3 was found within WRC (ABI3, WAVE2 and CYFIP1), confirming the interrelationship between PI3K/AKT and ABI3.
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invasion of epithelial tumors, been associated with poor 
prognosis and appears to cooperate with the oncogene 
RAS [34]. Interestingly, ABI3 was previously reported to 
be present in WAVE2 complex in NIH3T3 cells, but the 
authors demonstrated that ABI3-based WAVE2 complex 
is functionally distinct from ABI1-based WAVE complex 
[18]. Other authors did not describe significant changes 
in the phosphorylation status of either AKT or in MAPK 
in malignant glioma cells following ABI3 expression [3]. 
Importantly, although PI3K is mainly associated with 
cell growth and proliferation signals downstream from 
growth factors, it has also been associated with actin 
cytoskeleton remodeling and this regulation may involve 
interactions of PI3K and WRC [38]. More precisely, the 
authors suggested that WAVE, ABI1 and p85 subunit of 
PI3K might interact to promote actin-polymerization. 
Therefore, not only the interaction of ABI3 with other 
canonical components of the WRC may differ slightly 
according to cell types, but also the mechanism by which 
ABI3 interferes with components of PI3K/AKT signaling 
pathways may diverge.
In summary, we here demonstrated that the non-
phosphorylated form of ABI3 might be associated with its 
tumor suppressor effects and also propose a mechanism by 
which ABI3 links with PI3K/AKT with WRC.
MATERIALS AND METHODS
Methods are described in greater details in 
Supplementary data.
Cell lines
Two follicular thyroid carcinoma cell lines were 
used. The WRO (UCLA RO-82W-1) was kindly donated 
by Alfredo Fusco (Facoltà di Medicina e Chirurgia, 
University Federico II, Naples, Italy). FTC133 was 
purchased from the European Collection of Authenticated 
Cell Cultures (ECACC; cat# 94060902). WRO cell have 
a p53 mutation at codon 223 (P223L). FTC133 has a p53 
mutation at codon 273 (R273H). In addition, FTC133 
harbor a hemizygous deletion of PTEN with a nonsense 
point mutation (R130X) in the remaining allele.
Plasmids constructions and generation of stable 
cell clones
The full-length cDNA of ABI3 (accession number 
NM_016428.2) was cloned into phCMV2 expression 
vector containing a HA-tag upstream the multiple cloning 
site using EcoRI/BamHI restriction sites generating 
phCMV2-ABI3 vector. For generation of HA-GFP-
phCMV2 vector, GFP was subcloned from pcDNA-
FLAG-GFP. The HA-GFP-phCMV2 and HA-phCMV2 
empty vector and were used as negative controls.
Two follicular thyroid carcinoma cell lines, 
WRO (UCLA RO-82W-1) and FTC133 (ECACC; cat# 
94060902) were used. Cells were stably transfected with 
10 μg of each construct by electroporation using a Gene 
Pulser II Electroporation System (Bio-Rad, Hercules, CA). 
Pools were selected in complete medium supplemented 
with Geneticin 800 μg/mL (WRO) and 700 μg/mL 
(FTC133) (Invitrogen, Life Technologies, Grand Island, 
NY).
Proteome profiler antibody array
Cell lysates from WRO cells stably transfected with 
either ABI3 or control (empty vector) were incubated with 
Human Phospho-Kinase Array Kit (cat. # RY003), which 
detects relative phosphorylation levels of 46 intracellular 
serine/threonine/tyrosine kinases, and Human Apoptosis 
Array Kit (cat# ARY009), which detects levels of 35 
apoptosis-related proteins (R&D Systems, Minneapolis, 
MN). The intensity score of each duplicated spot was 
measured using ImageQuant LAS4000 Analyzer (GE 
Healthcare, Chicago, IL) and quantified using ImageQuant 
TL software (GE Healthcare). The averaged intensity was 
calculated by subtracting the averaged background signal, 
according to the manufacturer’s instructions. Fold changes 
were calculated based on the average density values of 
each protein expressed from WRO ABI3 expressing cells 
divided by the average density values of control cells.
Functional enrichment analysis
In order to visualize enriched pathways, the list of 
proteins that were found differentially expressed in WRO 
cells expressing ABI3, compared to the control, were 
upload at Enrichr analysis tool available online (http://
amp.pharm.mssm.edu/Enrichr/).
HA-tag immunoprecipitation (HA-IP) and mass 
spectrometry analysis
The lysates of WRO cells expressing the HA-tagged 
proteins (ABI3 and GFP) were incubated at 4°C for 
overnight with an EZview Red Anti-HA agarose Affinity 
Gel (Sigma Aldrich, St. Louis, MO) on a rocking platform. 
The recovered gel was washed three times with wash 
buffer (50 mM Tris-HCl pH=8.0, 100 mM NaCl). Bound 
proteins were eluted by competition with a synthetic 
HA peptide (300 ng/μL) (Sigma Aldrich). The resultant 
immunoprecipitation eluates were directly analyzed 
by liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS). Proteins from the HA-ABI3 
and HA-GFP pull-downs were denatured, reduced and 
alkylated. Four micrograms of peptides were analyzed in 
triplicate by LC-MS/MS in a Thermo Scientific Easy-nLC 
1000 system coupled to a LTQ Orbitrap XL ETD (mass 
spectrometry facility RPT02H PDTIS, Fiocruz Parana). 
The ten most intense ions were sequentially isolated and 
fragmented in the linear ion trap using collision-induced 
dissociation at a target value of 30,000. Peaklist picking, 
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protein identification, quantification, and validation were 
obtained using the MaxQuant platform (version 1.5.2.8). 
Antibodies used in this study are detailed in supplementary 
data (Supplementary Table 4). Proteomic data analysis is 
described in details in supplementary data.
Protein G-sepharose immunopreciptation with 
WAVE2 antibody
For WAVE2 immunoprecipitation (WAVE2-IP), 
WRO cells expressing the HA-tagged proteins (ABI3 and 
GFP) were lysate and incubated at 4°C overnight with 1:50 
WAVE2 antibody (Supplementary Table 4) on a rocking 
platform. After antibody incubation, Protein  beads were 
coupled to the extract for 3 h at 4°C in a rocking platform 
and washed three times with lyses buffer. Complexes were 
eluted from the beads with 0.1 M glycine-HCl pH 2.2 and 
neutralized with 1 M Tris-HCl pH=8.0. Eluted proteins 
were used in western blot analysis.
Alkaline phosphatase treatment
Cells lysates from WRO and FTC133 cells 
expressing ABI3 were treated with 1U/μg of protein of 
Calf Intestinal Alkaline Phosphatase (CIP, New England 
Biolabs) at 37°C for 1 h. Cell lysates untreated with CIP 
were used as negative control.
Thyroid samples
The series consists of 23 thyroid samples (7 normal 
thyroid tissues and 16 follicular thyroid adenoma) 
obtained from patients who underwent thyroid surgery at 
Hospital São Paulo (Universidade Federal de São Paulo), 
conducted under the approval of the Review Boards and 
Research Ethical Committee.
Total RNA was isolated from thyroid samples 
and Cell lines using TRIzol reagent (Invitrogen, Life 
Technologies, Grand Island, NY). RNA was reverse 
transcribed into cDNA using Super-Script III Reverse 
Transcriptase kit with an oligo(dT)12–18 primers. An 
aliquot (1μL) of cDNA was used in a PCR reaction 
containing SYBR Green PCR Master Mix (Applied 
Biosystems, Life Technologies) and 3,2 pmol of each 
specific primer for the target genes (ABI3, WAVE2 and 
CYFIP1) or reference gene (RPS8) (Supplementary Table 
5). The relative expression (RE) was calculated according 
to the comparative ΔΔCt method and used to correlate the 
expression of ABI3/WAVE2/CYF1P1.
Analysis of phosphorylation sites in ABI3 and 
site-directed mutagenesis
A search for putative phosphorylation sites of 
human ABI3 was performed using ABI3 data registered 
in the public databases (Supplementary Table 3) and 
candidates residues were submitted to Motif Scan 
analysis at Scansite 3 (http://scansite3.mit.edu/). This 
combined analysis revealed S342 as a likely candidate 
site for phosphorylation (Supplementary Table 3). To 
determine whether this residue (S342) is phosphorylated, 
the candidate serine was mutated to alanine (S342A) using 
the QuikChange Lightning Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA) according 
to the manufacturer’s instructions. The mutant plasmid 
(phCMV2-ABI3-S342A) was stable transfected into WRO 
and FTC133 cells and the expressed mutant protein was 
evaluated by western blot analysis.
LY294002 treatment
As ABI3 is likely to be phosphorylated by AKT 
on Serine residue 342, we further evaluate the impact 
of PI3K/Akt pathway on the phosphorylation of ABI3 
using LY294002, a potent inhibitor of PI3K that lead to 
the dephosphorylation of AKT at both T308 and S473. 
To this end, WRO and FTC133 cells expressing ABI3 
were treated for 2 h with 20 μM of the LY294002 (Cell 
Signaling Technology). Cells were collected, lysed and 
submitted to western blot analysis.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism v5.01 Software (GraphPad Software). We used 
Student t test or Mann-Whitney test. Results were 
expressed as mean±SD and P<0.05 was considered 
statistically significant.
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